Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J. Coombs RW, et al. Among authors: johnson va. J Infect Dis. 1996 Oct;174(4):704-12. doi: 10.1093/infdis/174.4.704. J Infect Dis. 1996. PMID: 8843206
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR. Japour AJ, et al. Among authors: johnson va. J Infect Dis. 1995 May;171(5):1172-9. doi: 10.1093/infdis/171.5.1172. J Infect Dis. 1995. PMID: 7538548
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. D'Aquila RT, et al. Among authors: johnson va. Ann Intern Med. 1995 Mar 15;122(6):401-8. doi: 10.7326/0003-4819-122-6-199503150-00001. Ann Intern Med. 1995. PMID: 7856987 Clinical Trial.
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Welles SL, et al. Among authors: johnson va. J Infect Dis. 1996 Oct;174(4):696-703. doi: 10.1093/infdis/174.4.696. J Infect Dis. 1996. PMID: 8843205
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Marschner IC, et al. Among authors: johnson va. J Infect Dis. 1998 Jan;177(1):40-7. doi: 10.1086/513823. J Infect Dis. 1998. PMID: 9419168 Clinical Trial.
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Hirsch MS, et al. Among authors: johnson va. Clin Infect Dis. 2003 Jul 1;37(1):113-28. doi: 10.1086/375597. Epub 2003 Jun 23. Clin Infect Dis. 2003. PMID: 12830416
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Paredes R, et al. Among authors: johnson va. J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543. J Infect Dis. 2010. PMID: 20102271 Free PMC article.
155 results